Calls to expand access to oral COVID-19 drugs as expiry dates loom

23 June 2022 - Thousands of doses of expensive anti-viral drugs could be wasted if more Australians do not become ...

Read more →

EMA recommends Valneva’s COVID-19 vaccine for authorisation in the EU

23 June 2022 - EMA has recommended granting a marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva for use in ...

Read more →

EMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 17

23 June 2022 - EMA’s CHMP has recommended granting an extension of indication for the COVID-19 vaccine Nuvaxovid to include use ...

Read more →

COVID-19 vaccine weekly safety report (23 June 2022)

23 June 2022 - To 19 June 2022, the TGA has received 581 reports which have been assessed as likely to ...

Read more →

New $11 million winter vaccine communication campaign and availability of antivirals

22 June 2022 - The Australian Government today launched an $11 million six-week campaign to encourage people to get vaccinated for ...

Read more →

EFPIA and Vaccines Europe are deeply disappointed about the decision taken by World Trade Organization at the Ministerial Conference to endorse a TRIPS waiver for COVID-19 vaccines

17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...

Read more →

Start of rolling review for adapted Spikevax COVID-19 vaccine

17 June 2022 - EMA has started a rolling review for a version of Spikevax adapted to provide better protection ...

Read more →

Moderna receives FDA authorisation for emergency use of its COVID-19 vaccine for children 6 months of age and older

17 June 2022 - mRNA-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, ...

Read more →

Pfizer-BioNTech COVID-19 vaccine receives FDA emergency use authorisation for children 6 months through 4 years of age

17 June 2022 - In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 vaccine elicited a strong immune response in this ...

Read more →

COVID-19 vaccine weekly safety report (16 June 2022)

16 June 2022 - To 12 June 2022, the TGA has received 584 reports which have been assessed as likely to ...

Read more →

Start of rolling review for adapted Comirnaty COVID-19 vaccine

15 June 2022 - EMA has started a rolling review for a version of Comirnaty adapted to provide better protection ...

Read more →

Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as a booster in individuals aged 18 and over

13 June 2022 - In Australia, Nuvaxovid is the first protein-based COVID-19 vaccine registered for use as a booster regardless ...

Read more →

PHARMAC seeks views on access criteria for COVID-19 treatments

14 June 2022 - PHARMAC is seeking feedback on access criteria for two new COVID-19 treatments – tixagevimab with cilgavimab ...

Read more →

IP waiver for COVID vaccines misses the mark in vaccinating the world

14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...

Read more →

COVID-19 vaccine weekly safety report (9 June 2022)

9 June 2022 - To 5 June 2022, the TGA has received 577 reports which have been assessed as likely to ...

Read more →